EP1305074A2 - Catheter d'administration de medicaments specifiques de cibles - Google Patents

Catheter d'administration de medicaments specifiques de cibles

Info

Publication number
EP1305074A2
EP1305074A2 EP01954960A EP01954960A EP1305074A2 EP 1305074 A2 EP1305074 A2 EP 1305074A2 EP 01954960 A EP01954960 A EP 01954960A EP 01954960 A EP01954960 A EP 01954960A EP 1305074 A2 EP1305074 A2 EP 1305074A2
Authority
EP
European Patent Office
Prior art keywords
medical catheter
catheter
restrictor
distal end
connector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01954960A
Other languages
German (de)
English (en)
Inventor
Dennis D. Elsberry
Chris Christiansen
Mary M. Morris
Douglas O. Hankner
Robert C. Hamlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/625,751 external-priority patent/US6945969B1/en
Application filed by Medtronic Inc filed Critical Medtronic Inc
Publication of EP1305074A2 publication Critical patent/EP1305074A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/16877—Adjusting flow; Devices for setting a flow rate

Definitions

  • This invention relates to medical catheters for target specific drug delivery.
  • U.S. Patent No. 3,640,269 describes a fluid delivery assembly having two flexible fluid-impermeable tubes open at one end and provided with an enlarged flexible permeable bag at the delivery segment.
  • This bag is comprised of a membrane having uniform porosity less than 0.5 microns and having a water permeability of at least 60 mL/minute/cm as a description of fluid permeability. While this design is capable of uniform fluid delivery to tissues adjacent to the permeable bag, a disadvantage of this assembly is its inability to be specifically targeted to a patient site due to the flexible distal bag.
  • a new medical catheter has now been discovered that provides uniform distribution of therapeutic agents to a targeted patient site.
  • the medical catheter of the present invention has a unique structure that permits it to be accurately placed so that it can uniformly distribute therapeutic agents to the targeted patient site.
  • the catheter has at least two distal ends, and a proximal end joined to the two distal ends via a connector, such as a AY@ connector having three legs.
  • a connector such as a AY@ connector having three legs.
  • the two distal ends and the proximal end are each located at a separate ends of the legs of the connector.
  • restrictors are placed in each leg of the connector.
  • a restrictor is a structure that provides a significant pressure drop when fluid flows through that structure.
  • the restrictors of the present invention provide structure to balance the flow for a multiple catheter system.
  • the restrictors can be made of any suitable material, e.g. a powder material such as sintered metal powder.
  • diffusers are placed at the distal ends.
  • a diffuser is a structure that diffuses and delivers a therapeutic agent over a large surface area as opposed to a single point source.
  • the diffusers and restrictors which are in each leg having a distal end, are separated from each other.
  • the diffuser is at the tip of each distal end, and the each restrictor is upstream of the distal end.
  • This construction is particularly useful for delivery of drugs via multiple catheter ends. For example, drug delivery to the two different hemispheres of the brain may be achieved, and the present invention can deliver drugs to each hemisphere substantially equally because of the restrictor(s) upstream of the distal ends, rather than at the distal ends as are the diffusers.
  • the following benefits are obtained by separating the diffuser and the restrictor: (1) increase in design options for the catheter tip; (2) improved reliability of catheter tip that is implanted in the brain tissue; and (3) reduced need to test the restrictor structure for biostability.
  • a restrictor is placed upstream of the Y connector as well, so that there is a restrictor in all three legs of the catheter joined by the Y connector.
  • This construction provides additional benefits. For example, having the restrictor upstream of the Y connector acts as a pre-filter, and thus removes any particulates prior to the Y connector.
  • This pre-filter function reduces particulates to the restrictors downstream of the Y connector, thus reducing the potential for different pressure drops and flow rates through the restrictors downstream of the Y connector, and ultimately the flow rate of the delivered drug through the diffusers at the distal ends.
  • this embodiment eliminates the possibility for insertion of a catheter where only one restrictor is downstream of the Y connector, and one restrictor is upstream of the Y connector.
  • the catheter of the present invention comprises a rigid assembly having a rigid tube for positioning the distal end of the catheter near a targeted patient site or sites, the distal end of the catheter has a rigid porous delivery segment having a porosity less than
  • the catheter of the present invention has a rigid assembly having an open tube having a distal end, the distal end having sintered metal powder, for example, metal microspheres to provide uniform porosity of the delivery segment.
  • the distal end comprises at least one uniform surface made of sintered metal powder.
  • the sintered metal powder can be made of any light-weight, high tensile strength material, e.g., tungsten, titanium or tantalum.
  • the rigid assembly functions as both a diffuser and a restrictor.
  • the sintered metal rigid assembly of this embodiment can be fabricated using a single cavity carbon mold, and a mold insert.
  • the sintered metal rigid assembly can be fabricated using powdered metal and pyrogenic sintering, such as high pressure plus pyrogenic sintering.
  • Sintered metal rigid assemblies can be positioned at the distal ends of separate legs of a catheter for placement at multiple patient targets. The distal ends can each join to a connector (e.g., a AY@ connector) for connection to a single therapy source.
  • the sintered metal rigid assembly of this embodiment functions as both a fluid restrictor and a fluid diffuser.
  • the diffuser and restrictor functions can be combined, as in a membrane tip, or separated, with the restrictor being upstream of the diffuser in each leg of the catheter.
  • a radiopaque material can be used, such as tungsten, titanium or tantalum. These metals are non-magnetic, and therefore are safe within a magnetic imaging environment.
  • An objective of the present invention is to provide for multiple catheter ends for drug delivery arising from a single pump source.
  • the present invention provides a catheter construction that provides desired distribution in a targeted area of the patient, such as giving medications intraparenchymally into tissue. Drug delivery by the present invention can be to an organ, and uniform distribution to that organ may be desired.
  • Another objective of the present invention is to provide a catheter to diffuse a therapeutic agent over a larger surface area than from a single point source. This structure results in a decrease in fluid flux and reduces potential for damaging tissue near the infusion site. In order for equal or near equal bilateral drug delivery to occur, two distal ends are required since fluid delivered from one distal end to a target site at one hemisphere will not deliver fluid to the other hemisphere.
  • the present invention can be used for many drug delivery applications, including but not limited, to intraparenchymal or tissue infusion (such as brain tissue infusion), intrathecal drug delivery and intracerebral ventricular (ICV) drug delivery, or any drug infusion into a fluid filled space or to a tumor.
  • intraparenchymal or tissue infusion such as brain tissue infusion
  • intrathecal drug delivery and intracerebral ventricular (ICV) drug delivery
  • ICV intracerebral ventricular
  • Figure 3A illustrates an embodiment of the catheter of the present invention in combination with device 20.
  • Figure 3B illustrates another embodiment of the catheter of the present invention in combination with device 20.
  • Figure 3C illustrates another embodiment of the catheter of the present invention in combination with device 20, this embodiment having two diffuser and restrictor distal catheter segments.
  • Figure 3D illustrates another embodiment of the present invention in combination with device 20, this embodiment having more than two diffuser and restrictor distal catheter segments.
  • Figure 4A illustrates another embodiment of the catheter of the present invention in combination with device 20, this embodiment having a separate restrictor placed between each diffuser distal catheter segment and connector 50.
  • Figure 4B illustrates another embodiment of the present invention in combination with device 20, this embodiment having multiple connectors 50, and multiple diffuser distal catheter segments with separate restrictors placed between each diffuser distal catheter segment and a corresponding connector 50.
  • Figure 5 A illustrates another embodiment of the catheter of the present invention in combination with device 20, this embodiment having separate restrictors placed between each diffuser distal catheter segment and a corresponding connector 50, and a restrictor 90 placed between proximal end 24 and the first connector 50 downstream of proximal end 24.
  • Figure 5B shows the same structure as Figure 4B, except that in this other embodiment of the present invention, a restrictor 90 is placed between proximal end 24 and the first connector 50 downstream of proximal end 24.
  • Figure 6 is a cross section view of one embodiment of a diffuser of the present invention taken from its distal end, which illustrates openings that are tapered as they extend from the outside diameter of the diffuser to the inside diameter of the diffuser.
  • Figure 7 is the side view of one embodiment of the diffuser of the present invention.
  • catheter 22 has a proximal end 24, and distal ends 26 and 26'. Distal ends 26 and 26' are connected to catheter 22, which splits at a AY@ connector 50. Distal end 26 is positioned in the right anterior cerebral cortex 16, and distal end 26' is positioned in the left anterior cerebral cortex 16'. Proximal end 24 is attached device 20, which can be an implantable infusion pump. While two distal ends are shown, the present invention can have one or more than two distal ends. As further shown in the embodiment depicted in Figure 2, catheter 22 has a catheter portion 10 downstream of device 20 and upstream of connector 50.
  • Catheter portion 10 preferably comprises an .elongated tubular wall 30 defining a central lumen 32.
  • catheter 22 begins at proximal end 24 and terminates at distal end 26.
  • distal end 26 has a catheter tip 34.
  • Proximal end 24 defines an opening 17.
  • Lumen 32 is defined by tubular wall 30.
  • Tubular wall 30 terminates at end 36.
  • catheter tip 34 is attached to tubular wall 30.
  • Catheter tip 34 has a lumen 38 to receive a drug from lumen 32, which can receive a drug pumped from device 20.
  • Tubular portion 30 ends at end 36.
  • the length of the portion of catheter tip 34 that is exposed to patient tissue is represented by a distance Ax@.
  • catheter 22 of the present invention comprises a rigid assembly having a rigid tubular wall 30 for positioning the distal end 26 of the catheter 22 near a targeted patient site, the distal end 26 having a rigid porous portion or drug delivery segment 60 made of a sintered microsphere material having aporosity less than 0.50 microns for achieving homogenous delivery to the targeted patient site.
  • rigid porous drug delivery segment 60 comprises sintered metal microspheres to provide uniform porosity.
  • a drug can be pumped from device 20, through opening 17, through lumen 32, through lumen 38, and through porous drug delivery segment 60 to a targeted patient site.
  • delivery segment 60 can also be referred to as a combination diffuser and restrictor. In other words, delivery segment 60 restricts flow of a fluid containing a therapeutic drug and also diffuses that fluid so that the fluid is distributed to and emitted from the outer surface of delivery segment 60 that is exposed to a targeted patient site.
  • the sintered metal powder of the delivery segment 60 defines multiple pores or porous openings 25.
  • the sintered metal powder is made of any light-weight, high tensile strength material, e.g., tungsten, titanium or tantalum.
  • the sintered rigid metal assemblies can be fabricated using a single cavity carbon mold, and a mold insert. Alternatively, the rigid metal assembly can be pressed into a green part using high pressure and sintered using heat to convert the green part to a fused structure (i.e, without carbon molds). Microspheres can be compressed together in each mold with pyrogenic processing.
  • a radiopaque material can be used, such as tungsten, titanium or tantalum. These metals are non-magnetic, and therefore are safe within a magnetic imaging environment.
  • the desired porosity of the sintered porous tip can be selected upon the diameter of the metal powder spheres used in the mold fabrication process.
  • the maximal dimensional distance between adjacent microspheres i.e., pore size
  • microsphere diameter is directly related to microsphere diameter, and is preferably as follows:
  • the distal end has a porous tip or a closed end, wherein the catheter tip is preferably composed of porous material such as polysulfone hollow fiber, manufactured by Amicon, although polyethylene, polyamides, polypropylene and expanded polytefrafluoroethlyene (ePTFE) are also suitable, and is preferable porous along its entire length to enable indomethacin to flow into the hippocampus, and the preferred pore size is approximately ranged between 0.1-0.2 microns. See Col. 5, line 64 through Col. 6, line 4 of U.S.
  • porous material such as polysulfone hollow fiber, manufactured by Amicon, although polyethylene, polyamides, polypropylene and expanded polytefrafluoroethlyene (ePTFE) are also suitable, and is preferable porous along its entire length to enable indomethacin to flow into the hippocampus, and the preferred pore size is approximately ranged between 0.1-0.2 microns. See Col. 5, line
  • Patent No. 5,846,220 differs from U.S. Patent No. 5,846,220, because, among other things, the present invention has much larger pore sizes, i.e., about 0.3 to 6.2 microns, and the porous material in the present invention is preferably made from sintered metal microspheres.
  • Figure 3B Another embodiment is shown in Figure 3B. This embodiment is similar to Figure 3 A, except that there is a side opemng 29 defined in distal end 26, and delivery segment 60 is positioned at side opening 29. Alternatively, delivery segment 60 can be positioned over or under side opening 29, relative to tubular wall 30. Side opening 29 can be incorporated into other embodiments shown and/or described herein.
  • Figure 3C Another embodiment is shown in Figure 3C.
  • Figure 3C is similar to Figure 3A, except there are two distal ends, 26 and 26', two drug delivery segments 60, and two legs 80 and 80' connected to a connector 50 and corresponding distal ends 26 and 26'.
  • This embodiment can be referred to as a catheter having two diffuser/restrictor catheter segments. This embodiment can be used to deliver a drug to two targeted patient sites.
  • FIG. 3D An alternative embodiment is shown in Figure 3D.
  • This embodiment is the same as that shown in Figure 3C, except that there are more than one connector 50, and more than two distal ends (in this embodiment, two distal ends 26 and two distal ends 26', for a total of four distal ends), more than two delivery segment portions 60, more than one catheter portion 10, and more than two distal tips 34 having lumens 38 to receive a drug from lumens 32. While four distal ends are shown, the present invention can have any number of distal ends as may be desired for drug delivery to targeted patient sites.
  • Connectors 50 are used to connect the proximal end 24 to catheter portions 10 and catheter portions 10 to legs 80 and 80'.
  • This embodiment can be referred to as catheter having multiple diffuser/restrictor catheter segments. This embodiment can be used to deliver a drug to more than two patient sites.
  • FIG. 4A Another embodiment of the present invention is shown in Figure 4A.
  • This embodiment has many of the same elements previously described for other embodiments, and in particular, the embodiment shown in Figure 3C.
  • the embodiment shown in Figure 4 A has a catheter 22 having at least two distal ends 26 and 26', and catheter portion or leg 10 joined to each distal end with a connector 50.
  • restrictors 70 and 70' are placed in each legs 80 and 80', which are downstream of connector 50.
  • Restrictors 70 and 70' can be made of any suitable material, including but not limited to, e.g. sintered metal powder, which is previously described above, or a material that provides a small diameter fluid path or capillary tubes.
  • the drug delivery segment (i.e., diffuser) 60 and restrictors 70 and 71' are separated from each other.
  • the drug delivery segment 60 is at tip 34 of each of the distal ends 26 and 26', and the restrictors 70 and 71' are upstream of distal ends 26 and 26', respectively.
  • This construction is particularly useful for delivery of drugs via multiple (more than one) catheter ends.
  • drug delivery to the two different hemispheres of the brain may be desired, and the present invention can deliver drugs to each hemisphere substantially equally because of the restrictors upstream of the distal ends, rather than at the distal ends as are the diffusers.
  • the following benefits are obtained by separating the diffuser and the restrictor: (1) increase in design options for the catheter tip; (2) improved reliability of catheter tip that is implanted in the brain tissue; and (3) reduced need to test the structure of the restrictor for biocompatibility.
  • FIG. 4B An alternative embodiment is shown in Figure 4B.
  • This embodiment is the same as that shown in Figure 4 A, except that there is more than one connector 50, more than two distal ends (in this embodiment, two distal ends 26, and two distal ends 26' for a total of four distal ends), more than two delivery segment portions 60, more than one catheter portion 10, more than one leg 80, more than one leg 80', and more than two distal tips 34 having a lumen 38 to receive a drug from lumen 32.
  • the connectors 50 are used to connect catheter portions 10 to the proximal end 24. This embodiment can be used to deliver a drug to more than two targeted patient sites.
  • Figure 5 A shows the same structure as Figure 4A, except that in tins other embodiment of the present invention, a restrictor 90 is placed upstream of connector 50 as well, so that there is a restrictor in legs 80, 80' and catheter portion 10 of the catheter 22 joined by connector 50.
  • This construction provides additional benefits. For example, having the restrictor 90 upstream of the connector 50 acts as a pre-filter, and thus removes any particulates prior to connector 50.
  • This pre-filter function reduces particulates to the restrictors 70 and 70' downstream of connector 50, thus reducing the potential for different pressure drops and flow rates through the restrictors 70 and 70' downstream of connector 50, and ultimately the flow rate of the delivered drug through the diffusers or delivery segments 60 at the distal ends.
  • this embodiment eliminates the possibility for incorrect insertion of a catheter where only one restrictor is downstream of connector, and one restrictor is upstream of connector 50, and one leg 80 or 80' not having a restrictor.
  • Figure 5B shows the same structure as Figure 4B, except that in this other embodiment of the present invention, a restrictor 90 is placed between proximal end 24 and the first connector 50 downstream of proximal end 24, to deliver a drug to more than two targeted patient sites.
  • the drug fluid is pushing through many small pores of the drug delivery segment 60, and restrictors 70, 70' and
  • the delivered drug fluid follows a tortuous path.
  • the sum of the resistance to flow through multiple catheter distal ends is preferably equal so that equal flow is through the multiple catheter distal ends is obtained.
  • the diffuser i.e., the drug delivery segment 60 shown in Figures 4 A, 4B, 5 A and 5B, can comprise any suitable structure.
  • the diffuser can comprise material having laser drilled holes having 0.001-0.005 inches diameter, and about 20-100 holes per diffuser.
  • the most distal of forty holes having 0.005 inches in diameter should have 76% of the flow compared to the most proximal hole (total flow 1 microliters/minute).
  • the distal hole should have 99.95% of the flow compared to the proximal hole.
  • porous materials such as sintered metal, sintered polyethylene, or porous PTFE (i.e., Teflon) have diffuser capability.
  • these structures are good diffusers at flow rates of about 1 microliter/minute to about 20 microliters/minute.
  • a permeability constant of less than about 30,000 and a bubble point of less than about 10 psi is preferred.
  • the restrictor creates a pressure drop of about 2-10 psi for a flow rate of about 10 microliters/minute, variation in interstitial pressure (less than 0.5 psi) will not create an imbalance of flow in the two catheter legs for a desired flow rate of about 1-10 microliters/minute.
  • the material for the restrictor must be very tortuous and have a significant length (i.e., thickness).
  • a permeability constant of less than about 5,000 and a bubble point of less than about 10 psi is preferred. Since the restrictor is separated from the diffuser in this embodiment, the dimensions and materials are not limited to those typically considered acceptable for intraparenchymal implant.
  • Acceptable materials for restrictors given the larger lengths possible outside the brain are sintered porous metals, and sintered and/or porous polymers.
  • Methods of manufacture and materials for the restrictors of the present invention include, but are not limited to, thin sheet filter (e.g., polyethersulfone or polypropylene, from Pall Corporation (East Hills, NY)), polycarbonate membrane (from Osnionics, Inc. (Minnetonka, MN)), polyvinylidine fluoride from Millipore Corporation (Bedford, MA)), depth filters from sintered metal (from Mott, Inc. (Farmington,
  • the restrictor is a depth filter since it does not have disadvantages that the other materials may have.
  • Sheet membranes have a disadvantage in that they have very small pores that may be prone to clogging and require a high pressure to pass air through the wet membrane (i.e., bubble point).
  • Orifice-type retrictors have the disadvantage of pressure drop that is extremely sensitive to diameter, thereby making it difficult and expensive to match two retrictors of this type to achieve substantially equal flow.
  • the restrictor should provide a large pressure drop.
  • K permeability constant
  • F flow rate
  • D viscosity for the fluid
  • T thickness of porous path
  • A surface area delta
  • P pressure delta
  • the features provided by this embodiment include: 1. Separate diffuser and restrictor features for bilateral intraparenchymal drug delivery catheter. 2. Use of simple diffusers that have insufficient tortuosity of the porous structure to make acceptable restrictors.
  • the present invention provides for multiple catheter ends for drug delivery. More specifically, the present invention provides for multiple catheter ends, e.g.
  • the present invention also provides a catheter to diffuse a therapeutic agent over a large surface area than from a single point source.
  • the benefits of this structure is that it decreases the fluid flux and reduces the change of damaging patient tissue.
  • two catheters are required. It is usually desirable to have equal flow in both catheters to deliver equal amounts of drug to both brain hemispheres.
  • the present invention can be used for many drug delivery applications, including but not limited to intraparenchymal tissue delivery, intrathecal drug delivery, and infra-cerebral ventricular (ICV) drug delivery.
  • ICV infra-cerebral ventricular

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention porte sur un cathéter médical comprenant: une extrémité proximale présentant une ouverture pour des liquides contenant un produit thérapeutique, une extrémité distale présentant au moins une ouverture, et une partie poreuse recouvrant ladite ouverture. Dans l'une des exécutions, le cathéter médical comprend: une extrémité proximale présentant une ouverture pour des liquides contenant un produit thérapeutique, au moins deux extrémités distales, l'extrémité proximale étant raccordée aux extrémités distales par un connecteur, et les extrémités distales présentant chacune au moins une ouverture, un diffuseur couvrant les ouvertures de chacune des extrémités distales, et deux étrangleurs séparés placés en aval du connecteur et en amont de chacune des extrémités distales et égalisant sensiblement les flux traversant lesdites extrémités distales. On peut également placer un étrangleur supplémentaire en amont du connecteur. Dans une autre exécution, un combiné diffuseur étrangleur recouvre les ouvertures de chacune des extrémités distales.
EP01954960A 2000-07-26 2001-07-26 Catheter d'administration de medicaments specifiques de cibles Withdrawn EP1305074A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US625751 2000-07-26
US09/625,751 US6945969B1 (en) 2000-03-31 2000-07-26 Catheter for target specific drug delivery
PCT/US2001/023434 WO2002007810A2 (fr) 2000-07-26 2001-07-26 Catheter d'administration de medicaments specifiques de cibles

Publications (1)

Publication Number Publication Date
EP1305074A2 true EP1305074A2 (fr) 2003-05-02

Family

ID=24507432

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01954960A Withdrawn EP1305074A2 (fr) 2000-07-26 2001-07-26 Catheter d'administration de medicaments specifiques de cibles

Country Status (3)

Country Link
EP (1) EP1305074A2 (fr)
AU (1) AU2001277171A1 (fr)
WO (1) WO2002007810A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7544196B2 (en) 2001-02-20 2009-06-09 Orthovita, Inc. System and kit for delivery of restorative materials
DE60306828T2 (de) * 2002-03-21 2007-08-02 Ed. Geistlich Söhne AG für chemische Industrie, Wolhusen Vorrichtung für Behandlung eines Tumors im zentralen Nervensystem
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US8216177B2 (en) 2002-12-23 2012-07-10 Medtronic, Inc. Implantable drug delivery systems and methods
US8043281B2 (en) 2002-12-23 2011-10-25 Medtronic, Inc. Catheters incorporating valves and permeable membranes
US8246602B2 (en) 2002-12-23 2012-08-21 Medtronic, Inc. Catheters with tracking elements and permeable membranes
EP1938852B1 (fr) 2002-12-23 2010-04-07 Medtronic, Inc. Systèmes de réglage de densité de solution de médicament
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7678103B2 (en) * 2003-06-12 2010-03-16 Cordis Corporation Orifice device for delivering drugs at low fluid flow rates
US7108762B2 (en) * 2003-06-12 2006-09-19 Cordis Corporation Method for manufacturing an orifice mechanism capable of low fluid flow rates
US7211076B2 (en) 2003-06-12 2007-05-01 Cordis Corporation Medical device for fluid delivery having low fluid flow rate
US8109922B2 (en) 2003-06-12 2012-02-07 Cordis Corporation Orifice device having multiple channels and multiple layers for drug delivery
US8491571B2 (en) 2003-06-12 2013-07-23 Cordis Corporation Orifice device having multiple channels with varying flow rates for drug delivery
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8845590B2 (en) * 2012-05-01 2014-09-30 Merit Medical Systems, Inc. Catheter with distal diffuser
US11638805B2 (en) * 2019-02-27 2023-05-02 Avent, Inc. Multi-headed catheter for fluid delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3469578A (en) * 1965-10-12 1969-09-30 Howard R Bierman Infusion device for ambulatory patients with flow control means
US3817248A (en) * 1972-11-06 1974-06-18 Alza Corp Self powered device for delivering beneficial agent
US4186745A (en) * 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
JPH0341967A (ja) * 1989-07-11 1991-02-22 Olympus Optical Co Ltd 薬剤徐放装置
US5931774A (en) * 1991-06-14 1999-08-03 Proxima Therapeutics, Inc. Inflatable devices for tumor treatment
FR2689403A1 (fr) * 1992-04-01 1993-10-08 Celsa Lg Dispositif d'injection d'un médicament via une chambre implantable et outil facilitant son utilisation.
WO1996033761A1 (fr) * 1995-04-28 1996-10-31 Medtronic, Inc. Systeme de catheter pour perfusion intraparenchymateuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0207810A3 *

Also Published As

Publication number Publication date
WO2002007810A2 (fr) 2002-01-31
WO2002007810A3 (fr) 2002-06-13
AU2001277171A1 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
US6551290B1 (en) Catheter for target specific drug delivery
US7153292B2 (en) Catheter for target specific drug delivery
WO2002007810A2 (fr) Catheter d'administration de medicaments specifiques de cibles
US7069634B1 (en) Method for manufacturing a catheter
US6093180A (en) Intraparenchymal infusion catheter system
US11833325B2 (en) Sprinkler cannula
US6056725A (en) Therapeutic method for treatment of alzheimer's disease
US6974448B2 (en) Method for convection enhanced delivery catheter to treat brain and other tumors
CA2371798C (fr) Catheter d'amenee de medicaments composite
US7189222B2 (en) Therapeutic method of treatment of alzheimer's disease
JP6498670B2 (ja) 薬剤送達、治療、およびモニタリングのためのシステムおよび方法
US20030045861A1 (en) Convection enhanced delivery catheter to treat brain and other tumors
US8784360B2 (en) Catheter systems having flow restrictors
EP0536296A4 (en) Method and catheter for intravascular drug delivery
CN112041017A (zh) 用于治疗性输送的注射端口
WO2003089031A1 (fr) Catheter spinal sous-arachnoidien destine au transport d'un liquide cephalo-rachidien
AU1958301A (en) Catheter with stylet lumen
JP2013526960A (ja) 組織注入装置及び方法
AU5545496A (en) Bioretentive filtered infusion catheter
WO2001008725A1 (fr) Dispositif d'administration pharmaceutique et utilisation de celui-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030225

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030509